Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.

Huang J, Wen D, Wang Q.

N Engl J Med. 2012 Nov 22;367(21):2052-3; author reply 2054. doi: 10.1056/NEJMc1211068#SA1. No abstract available.

PMID:
23171108
2.

Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.

Hong J, Deng SX, Xu J.

N Engl J Med. 2012 Nov 22;367(21):2053; author reply 2054. doi: 10.1056/NEJMc1211068#SA3. No abstract available.

PMID:
23171110
3.

Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.

Rao RC, Dlouhy BJ.

N Engl J Med. 2012 Nov 22;367(21):2053; author reply 2054. doi: 10.1056/NEJMc1211068#SA2. No abstract available.

PMID:
23171109
4.

Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.

Stalmans P, Benz MS, Gandorfer A, Kampik A, Girach A, Pakola S, Haller JA; MIVI-TRUST Study Group.

N Engl J Med. 2012 Aug 16;367(7):606-15. doi: 10.1056/NEJMoa1110823.

5.

Delayed full-thickness macular hole closure without vitreomacular traction release following ocriplasmin injection.

Abou Ltaif S, Herbert L.

BMJ Case Rep. 2015 Sep 10;2015. pii: bcr2015212181. doi: 10.1136/bcr-2015-212181.

6.

Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis.

Stalmans P, Duker JS, Kaiser PK, Heier JS, Dugel PU, Gandorfer A, Sebag J, Haller JA.

Retina. 2013 Nov-Dec;33(10):2003-11. doi: 10.1097/IAE.0b013e3182993ef8. Review.

PMID:
23881226
7.

Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome.

Singh RP, Li A, Bedi R, Srivastava S, Sears JE, Ehlers JP, Schachat AP, Kaiser PK.

Br J Ophthalmol. 2014 Mar;98(3):356-60. doi: 10.1136/bjophthalmol-2013-304219. Epub 2013 Dec 19.

PMID:
24357495
8.

Looking at ocriplasmin as a new option in eye disease.

Mitchell MD, Miller DM.

Drugs Today (Barc). 2012 Aug;48(8):519-24. doi: 10.1358/dot.2012.48.8.1848664.

PMID:
22916339
9.

Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole.

Gandorfer A, Benz MS, Haller JA, Stalmans P, Pakola SJ, Girach A, Kampik A, Toth CA, Jaffe GJ; MIVI-TRUST Study Group.

Retina. 2015 Jun;35(6):1151-7. doi: 10.1097/IAE.0000000000000508.

PMID:
25741816
10.

[Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].

Maier M, Abraham S, Frank C, Lohmann CP, Feucht N.

Ophthalmologe. 2017 Feb;114(2):148-154. doi: 10.1007/s00347-016-0322-9. German.

PMID:
27444007
11.

Ocriplasmin: a review of its use in patients with symptomatic vitreomacular adhesion.

Syed YY, Dhillon S.

Drugs. 2013 Sep;73(14):1617-25. doi: 10.1007/s40265-013-0124-1. Review.

PMID:
24062204
12.

Ocriplasmin-Induced Macular Hole Closure in the Absence of Vitreomacular Adhesion Release.

Modi YS, Singh RP.

Ophthalmic Surg Lasers Imaging Retina. 2015 Jun;46(6):677-9. doi: 10.3928/23258160-20150610-14.

PMID:
26114851
13.

[Clinical evaluation of ocriplasmin as a vitreolytic agent].

Li L, Du H, Li M, Hui Y.

Zhonghua Yan Ke Za Zhi. 2015 Feb;51(2):155-60. Chinese.

PMID:
25908008
14.

Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole.

Quezada-Ruiz C, Pieramici DJ, Nasir M, Rabena M, Steinle N, Castellarin AA, Dhoot D, Couvillion S, See RF, Avery RL.

Retina. 2015 Jun;35(6):1144-50. doi: 10.1097/IAE.0000000000000544.

PMID:
25961122
15.

Bilateral vitreomacular traction resolved with a single intravitreal ocriplasmin injection.

Katz RS.

Ophthalmic Surg Lasers Imaging Retina. 2014 May-Jun;45(3):239-42. doi: 10.3928/23258160-20140401-01. Epub 2014 Apr 7.

PMID:
24708167
16.

Pathology of Internal Limiting Membrane Specimens Following Intravitreal Injection of Ocriplasmin.

Schumann RG, Wolf A, Mayer WJ, Compera D, Hagenau F, Ziada J, Kampik A, Haritoglou C.

Am J Ophthalmol. 2015 Oct;160(4):767-78. doi: 10.1016/j.ajo.2015.06.020. Epub 2015 Jun 29.

PMID:
26133247
17.

Intravitreal ocriplasmin: A breakthrough in the treatment of vitreomacular traction?

Mec-Słomska AE, Adamiec-Mroczek J, Kuźmicz E, Misiuk-Hojło M.

Adv Clin Exp Med. 2017 May-Jun;26(3):527-531. doi: 10.17219/acem/62122. Review.

18.

Correspondence.

Primavera V, Querques G.

Retina. 2014 Dec;34(12):e39-40. doi: 10.1097/IAE.0000000000000384. No abstract available.

PMID:
25407235
19.

Reply: To PMID 23881226.

Stalmans P, Duker JS.

Retina. 2015 Apr;35(4):e28-9. doi: 10.1097/IAE.0000000000000597. No abstract available.

PMID:
25807179
20.

From the analysis of pharmacologic vitreolysis to the comprehension of ocriplasmin safety.

Morescalchi F, Gambicorti E, Duse S, Costagliola C, Semeraro F.

Expert Opin Drug Saf. 2016 Sep;15(9):1267-78. doi: 10.1080/14740338.2016.1208169. Epub 2016 Jul 20. Review.

PMID:
27388220

Supplemental Content

Support Center